Clear cell renal cell carcinoma: from biology to treatment
Simple Summary Over the past two decades, biological discoveries have transformed the
treatment strategies for renal cell carcinoma. These advances have led to the development …
treatment strategies for renal cell carcinoma. These advances have led to the development …
Loss of Von Hippel–Lindau (VHL) Tumor Suppressor Gene Function: VHL–HIF Pathway and Advances in Treatments for Metastatic Renal Cell Carcinoma (RCC)
Renal cell carcinoma (RCC) is a malignancy of the kidney originating from the tubular
epithelium. Inactivation of the von Hippel–Lindau tumor-suppressor gene (VHL) is found in …
epithelium. Inactivation of the von Hippel–Lindau tumor-suppressor gene (VHL) is found in …
[HTML][HTML] Soluble PD-L1 as an early marker of progressive disease on nivolumab
KM Mahoney, P Ross-Macdonald, L Yuan… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Soluble PD-L1 (sPD-L1) has been associated with worse prognosis in
numerous solid tumors. We determined sPD-L1 levels before and during nivolumab …
numerous solid tumors. We determined sPD-L1 levels before and during nivolumab …
Current landscape of genomic biomarkers in clear cell renal cell carcinoma
Context Dramatic gains in our understanding of the molecular biology of clear cell renal cell
carcinoma (ccRCC) have created a foundation for clinical translation to improve patient care …
carcinoma (ccRCC) have created a foundation for clinical translation to improve patient care …
Report from the international society of urological pathology (ISUP) consultation conference on molecular pathology of urogenital cancers: III: molecular pathology of …
Renal cell carcinoma (RCC) subtypes are increasingly being discerned via their molecular
underpinnings. Frequently this can be correlated to histologic and immunohistochemical …
underpinnings. Frequently this can be correlated to histologic and immunohistochemical …
Predictive biomarkers of response to immunotherapy in metastatic renal cell cancer
A Raimondi, P Sepe, E Zattarin, A Mennitto… - Frontiers in …, 2020 - frontiersin.org
Introduction In the last decades, the therapeutic decision-making approach to metastatic
renal cell cancer (mRCC) has dramatically changed thanks to the introduction in the …
renal cell cancer (mRCC) has dramatically changed thanks to the introduction in the …
Cabozantinib for the treatment of solid tumors: a systematic review
P Maroto, C Porta, J Capdevila… - … in medical oncology, 2022 - journals.sagepub.com
Background: Cabozantinib is approved, in various settings, for the treatment of renal cell
carcinoma, medullary thyroid cancer, and hepatocellular carcinoma, and it has been …
carcinoma, medullary thyroid cancer, and hepatocellular carcinoma, and it has been …
Anti-angiogenesis and immunotherapy: novel paradigms to envision tailored approaches in renal cell-carcinoma
A Argentiero, AG Solimando, M Krebs, P Leone… - Journal of Clinical …, 2020 - mdpi.com
Although decision making strategy based on clinico-histopathological criteria is well
established, renal cell carcinoma (RCC) represents a spectrum of biological ecosystems …
established, renal cell carcinoma (RCC) represents a spectrum of biological ecosystems …
Subgroup-independent mapping of renal cell carcinoma—machine learning reveals prognostic mitochondrial gene signature beyond histopathologic boundaries
Background: Renal cell carcinoma (RCC) is divided into three major histopathologic groups—
clear cell (ccRCC), papillary (pRCC) and chromophobe RCC (chRCC). We performed a …
clear cell (ccRCC), papillary (pRCC) and chromophobe RCC (chRCC). We performed a …
Epidemiology, risk assessment, and biomarkers for patients with advanced renal cell carcinoma
Renal cell carcinoma (RCC) accounts for 3% of adult malignancies and is the eighth leading
cause of cancer in the United States. 1 Worldwide, 400,000 people were diagnosed and …
cause of cancer in the United States. 1 Worldwide, 400,000 people were diagnosed and …